Tiffany Terra
Family · Monroe, LANPI 1689013427
Payments from drug & device makers
Across 153 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$706
- Teva Pharmaceuticals USA, Inc.$197
- Supernus Pharmaceuticals, Inc.$156
- Takeda Pharmaceuticals U.S.A., Inc.$137
- Astellas Pharma US Inc$104
- Bayer$97
- plus $866 from 25 others
What the payments were for
- Food & beverage$2,24299%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $706 |
| Teva Pharmaceuticals USA, Inc. | 17 | $197 |
| Supernus Pharmaceuticals, Inc. | 6 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $137 |
| Astellas Pharma US Inc | 6 | $104 |
| Bayer | 5 | $97 |
| Corium, LLC | 6 | $86 |
| Lilly USA, LLC | 5 | $72 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Genentech USA, Inc. | 12 | $67 |
| Ironwood Pharmaceuticals, Inc | 4 | $65 |
| Novo Nordisk | 3 | $49 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Ardelyx, Inc. | 2 | $42 |
| Abbott | 2 | $41 |
| Antares Pharma, Inc. | 2 | $40 |
| Abiomed | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Halozyme Inc | 1 | $20 |
| Pfizer | 1 | $20 |
| Stryker | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Amgen | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Tris Pharma Inc | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Smith+Nephew | 1 | $14 |
How this compares
$2,262 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 59 | $77,131 |
| OzempicSemaglutide | 21 | $29,932 |
| LinzessLinaclotide | 20 | $16,359 |
| TrintellixVortioxetine Hydrobromide | 13 | $11,502 |
| LantusInsulin Glargine,hum.Rec.Anlog | 17 | $3,404 |
| Dexlansoprazole DrDexlansoprazole | 18 | $3,319 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $2,195 |
| Gabapentin | 84 | $1,494 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 39 | $1,236 |
| Pantoprazole Sodium | 88 | $1,128 |
| Valsartan | 16 | $965 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $718 |
| Nebivolol Hcl | 14 | $636 |
| Levothyroxine Sodium | 85 | $609 |
| Clonazepam | 97 | $547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $72 | $77,13159 claims |
| Novo NordiskOzempic | $49 | $29,93221 claims |
| AbbVieLinzess | $706 | $16,35920 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $137 | $11,50213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Monroe
- Rebecca HoodMonroe$15K
- Gabrielle NicolleMonroe$14K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.